<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522687</url>
  </required_header>
  <id_info>
    <org_study_id>SHCH1501</org_study_id>
    <nct_id>NCT04522687</nct_id>
  </id_info>
  <brief_title>Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer</brief_title>
  <official_title>Observation of the Impact of Radiotherapy With or Without Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets for Patients With Thoracic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Cancer Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Cancer Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an observation, single center study to evaluate the alternations and prognostic&#xD;
      value of peripheral blood lymphocyte (PBL) in patients diagnosed with thoracic cancers,&#xD;
      including lung cancer, esophageal squamous cell carcinoma and thymic epithelial carcinoma&#xD;
      underwent radiotherapy with or without chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2012</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Five years</time_frame>
    <description>OS was defined as the time from the date of enrollment until death by any cause. Participants still alive at the time of data analysis were censored at the date of last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Five years</time_frame>
    <description>PFS was measured from the date of enrollment to the date of disease progression as defined by Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 or death due to any cause, whichever occurred first</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>NSCLC</condition>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Thymic Epithelial Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese patients diagnosed with NSCLC, esophageal squamous cell carcinoma or thymic&#xD;
        epithelial tumor.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age at least 18 years. ECOG PS 0-1. Pathologically confirmed NSCLC, esophageal squamous&#xD;
        cell carcinoma or thymic epithelial tumor.&#xD;
&#xD;
        Life expectancy of more than 3 months. Patients with no indications for palliative&#xD;
        radiotherapy in the opinion of the investigator.&#xD;
&#xD;
        Patients with a prior history of surgery are eligible if they have recovered adequately&#xD;
        from the toxicity and/or complications of surgery.&#xD;
&#xD;
        Signed informed consent for the use of fresh tumor biopsies before and during the&#xD;
        treatment.&#xD;
&#xD;
        Women of childbearing age and men must agree to use effective contraception during the&#xD;
        trial.&#xD;
&#xD;
        Adequate organ function within 1 week prior to the enrollment：&#xD;
&#xD;
          1. Adequate bone marrow function: hemoglobin ≥80g/L, white blood cell (WBC) count ≥ 4.0 *&#xD;
             10 ^ 9/L or neutrophil count ≥ 1.5 * 10 ^ 9/L, and platelet count ≥ 100 * 10 ^ 9/L;&#xD;
&#xD;
          2. Adequate hepatic function: total bilirubin &lt; 1.5 x upper limit of normal (ULN). Note:&#xD;
             If total bilirubin is &gt; 1.5 x ULN, direct bilirubin must ≤ ULN, Aspartate&#xD;
             aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5 ULN;&#xD;
&#xD;
          3. Adequate renal function: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50&#xD;
             mL/min;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pregnant or lactating women. History of any other malignancy. Patients in whom palliative&#xD;
        radiotherapy is indicated in the opinion of the investigator.&#xD;
&#xD;
        Active infection, congestive heart failure, myocardial infarction within the 6 months prior&#xD;
        to enrollment, unstable angina pectoris or cardiac arrhythmia.&#xD;
&#xD;
        Patients who have received tumor vaccine; or administration of live, attenuated vaccine&#xD;
        within 4 weeks before the start of treatment.&#xD;
&#xD;
        Mental disorders, drug abuse, and social condition that may negatively impact compliance in&#xD;
        the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Fan, MD</last_name>
      <phone>18017312298</phone>
      <email>fanming@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Cancer Hospital, China</investigator_affiliation>
    <investigator_full_name>Fan Min</investigator_full_name>
    <investigator_title>MD. PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

